SCHEMBL4898058

SCHEMBL4898058

O=C(c1cc(Cl)c(OCc2ccccc2)c(Cl)c1)N1CCNc2ccccc21

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AVPR1A P37288 3/20 0.44
GPBAR1 Q8TDU6 2/20 0.44
KDM4E B2RXH2 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
GAA P10253 1/20 0.40
MAPK1 P28482 1/20 0.40
NAAA Q02083 2/20 0.40
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
SLC22A12 Q96S37 1/20 0.39
GLRA1 P23415 1/20 0.39
BRD4 O60885 2/20 0.38
AVPR2 P30518 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
GRM5 P41594 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4895551 0.82 BRD4 (0.52) KDM4ESMN1; SMN2NAAAALDH1A1SLC22A12
SCHEMBL4899486 0.81 GPBAR1 (0.48) GPBAR1KDM4ENPC1RAB9ANAAA
SCHEMBL4903802 0.81 SLC22A12 (0.53) AVPR1AGPBAR1ALDH1A1SLC22A12BRD4
SCHEMBL4895457 0.80 LMNA (0.56) AVPR1ASMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL4900137 0.80 GAA (0.47) GPBAR1KDM4ESMN1; SMN2GAAALDH1A1
SCHEMBL4893108 0.80 POLB (0.58) GPBAR1KDM4ERAB9ANAAAMAPT
SCHEMBL4895480 0.80 AVPR2 (0.58) AVPR1AALDH1A1SLC22A12AVPR2
SCHEMBL4898984 0.79 SLC22A12 (0.52) KDM4ENPC1RAB9AMAPK1NAAA
SCHEMBL5015406 0.78 KDM4E (0.41) KDM4ENPC1RAB9ANAAAALDH1A1
SCHEMBL4901495 0.78 POLB (0.50) GPBAR1KDM4ENAAAALDH1A1AVPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080305169-A1 Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds JAPAN TOBACCO INC. (JP) 2008-12-11 US disclosed
US-20080064871-A1 Production Method of Nitrogen-Containing Fused Ring Compounds JAPAN TOBACCO INC. (JP) 2008-03-13 US disclosed
EP-1820515-A1 NITROGEN-CONTAINING FUSED RING COMPOUND AND USE THEREOF Japan Tobacco, Inc. (JP) 2007-08-22 EP disclosed
US-20070010670-A1 Nitrogen-containing fused ring compounds and use thereof JAPAN TOBACCO INC. (JP) 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080305169-A1 Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds NOD1, NLRP3, SLC10A1 AVPR1A 3879/4885GPBAR1 297/4885KDM4E 2953/4885
US-20070010670-A1 Nitrogen-containing fused ring compounds and use thereof NUDT1, NOD1, SLC28A1 AVPR1A 4230/4885GPBAR1 267/4885KDM4E 3266/4885
US-20080064871-A1 Production Method of Nitrogen-Containing Fused Ring Compounds NOD1, XDH, URB2 AVPR1A 4032/4885GPBAR1 1605/4885KDM4E 2773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.